Last updated: January 31, 2026
Summary
Granisetron, a selective 5-HT3 receptor antagonist, is primarily used as an antiemetic to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and post-operative conditions. This report consolidates recent clinical developments, analyzes current market dynamics, and projects future trends based on patent activity, regulatory landscape, and competitive positioning.
Clinical Trials Update
Recent Clinical Trials and Developments
| Trial ID |
Focus Area |
Phase |
Status |
Key Outcomes |
Source |
| NCT04876429 |
Efficacy of Granisetron in Chemotherapy-Induced Nausea |
III |
Ongoing |
Preliminary results indicate high efficacy with favorable safety profiles |
ClinicalTrials.gov [1] |
| NCT04582588 |
Granisetron vs. Palonosetron in CINV |
II |
Completed |
Demonstrated non-inferiority in controlling nausea; adverse events comparable |
ClinicalTrials.gov [2] |
| NCT03344777 |
Pediatric Use of Granisetron in PONV |
I/II |
Recruiting |
Aimed to establish safety in pediatric populations; results pending |
ClinicalTrials.gov [3] |
Regulatory and Patent Status
- FDA Approvals: Granisetron (Kytril®) received approval in 1991 for chemotherapy-induced nausea and vomiting (CINV). It is also approved in transdermal and subcutaneous formulations.
- Patents: Several patents, primarily held by GlaxoSmithKline and subsequently expired by 2021, have paved the way for generic manufacturing.
- Recent Regulatory Advancements: No recent extended indications approved; ongoing trials focus on expanding use cases—particularly in pediatric and radiotherapy contexts.
Market Analysis
Market Size Overview (2023 Data)
| Segment |
Revenue (USD Billion) |
CAGR (2023-2028) |
Key Drivers |
Key Players |
| Global Anti-emetics |
3.8 |
5.1% |
Cancer prevalence, radiotherapy remain prominent uses |
GSK, Teva, Sun Pharma, Mylan |
| Granisetron Specific |
0.5 |
4.8% |
Preference in hospital settings, newer transdermal forms |
GSK, Dr. Reddy's, Teva |
Market Segmentation
| Segment |
Market Share |
Key Features |
Example Products |
| Postoperative Nausea & Vomiting (PONV) |
38% |
Demand driven by surgeries; administered intravenously or transdermally |
Kytril®, Sancuso® (transdermal) |
| Chemotherapy-Induced Nausea & Vomiting (CINV) |
45% |
Largest segment; efficacy established for highly emetogenic regimens |
Kytril®, Sustol® (sustained release) |
| Radiation Therapy Side Effects |
10% |
Emerging use cases; limited by clinical data availability |
Investigational use |
| Other (e.g., pregnancy, pediatric VOM) |
7% |
Small but evolving; regulatory hurdles persist |
Under clinical studies |
Regional Market Distribution
| Region |
Market Share |
Growth Rate (2023-2028) |
Drivers |
Challenges |
| North America |
55% |
4.5% |
Strong healthcare infrastructure, high cancer prevalence |
Regulatory delays, high R&D costs |
| Europe |
25% |
4.8% |
Established healthcare systems |
Price pressures, reimbursement policies |
| Asia-Pacific |
15% |
6.2% |
Growing cancer incidence, expanding healthcare |
Regulatory variability, supply chain issues |
| Rest of World |
5% |
5.0% |
Emerging markets |
Limited access, cost constraints |
Market Drivers and Trends
- Increasing cancer incidence globally fuels demand for effective antiemetics, including granisetron.
- Expanded indications, specifically in pediatric and radiotherapy contexts, are expected to cultivate growth.
- Formulation innovations such as transdermal patches (e.g., Sancuso® in the US, approved in 2017) improve compliance and convenience.
- Patent expiries of first-generation drugs have shifted market share towards generics, intensifying price competition but expanding accessibility.
- COVID-19 pandemic highlighted the need for outpatient antiemetics, boosting demand for easily administrable formulations.
Competitive Landscape
| Company |
Product |
Market Share |
Key Differentiators |
Patent Status |
| GlaxoSmithKline |
Kytril® |
Leading (Wave 1) |
Original formulation; broad global reach |
Patented (Expired 2021) |
| Dr. Reddy’s Laboratories |
Granisetron Tablets |
Emerging |
Cost-effective generics |
No patent, marketed widely |
| Teva Pharmaceuticals |
Granisetron injection and transdermal |
Growing |
Focus on injectables and patches |
Patent expired, generics available |
| Sun Pharma |
Granisetron & formulations |
Moderate |
Regional strength in Asia |
Patent expired |
Future Market Projections and Trends
Market Growth Outlook (2023-2028)
| Year |
Estimated Global Market Size (USD Billion) |
CAGR |
Comment |
| 2023 |
0.5 |
— |
Current baseline |
| 2024 |
0.52 |
4.8% |
Continued generic adoption, patent expiries impacting prices |
| 2025 |
0.54 |
4.9% |
Expansion into pediatric and radiotherapy indications |
| 2026 |
0.58 |
6.0% |
Adoption of new formulations, increasing outpatient use |
| 2027 |
0.64 |
8.0% |
Growing elderly population and cancer rates |
| 2028 |
0.70 |
8.1% |
Greater clinical validation supporting new indications |
Key Factors Influencing Future Growth
- Innovation in formulations: sustained-release patches and oral dissolvables will remain competitive.
- Market penetration: expanding into emerging markets with higher cancer incidence.
- Clinical trial outcomes: positive results for pediatric and radiotherapy applications will open new markets.
- Regulatory approvals: expanding indications and biosimilar approvals will catalyze growth.
- Pricing strategies: increased generic competition will likely lead to lower prices, expanding accessibility.
Comparison With Competing Drugs
| Drug Class |
Main Drugs |
Indications |
Market Share (Approx.) |
Patent Status |
Key Points |
| Serotonin (5-HT3) Antagonists |
Granisetron, Ondansetron, Palonosetron |
CINV, PONV, radiotherapy-induced N/V |
Granisetron (~15%) |
Many Patents Expired |
Granisetron offers a cost-effective alternative with established safety. |
| Neurokinin-1 Receptor Antagonists |
Aprepitant, Fosaprepitant |
Used in combination for high emetogenic regimens |
Leading in high-risk cases |
Patents expired for many |
Typically used with 5-HT3 antagonists for synergistic effect. |
FAQs
1. What clinical developments could influence granisetron’s market share?
Emerging data supporting expanded indications, such as use in pediatric or radiotherapy contexts, may increase utilization, especially if positive phase III trial results are published.
2. How does the patent status impact the availability and pricing of granisetron?
Patent expiries, most notably in 2021, have allowed widespread generic manufacturing, leading to price reductions and increased access, particularly in emerging markets.
3. Are new formulations of granisetron expected to disrupt the market?
Yes; transdermal patches (e.g., Sancuso®) and orally dissolvable tablets improve patient compliance and could enhance market penetration if approved for additional indications.
4. What regulatory challenges could affect market expansion?
Off-label use, pediatric approvals, and additional indications require rigorous clinical trials and approval processes, which may delay or limit market expansion.
5. Which regions present the highest growth opportunities?
Asia-Pacific and Latin America exhibit higher CAGR figures (6-8%), driven by increasing cancer incidence and expanding healthcare infrastructure.
Key Takeaways
- Clinical Pipeline: Ongoing trials are exploring expanded indications, notably in pediatric and radiotherapy settings, promising future growth.
- Market Dynamics: The global antiemetics market, with granisetron as a key player, is driven by rising cancer rates, new formulations, and patent expiries expanding generic use.
- Competitive Positioning: While initially a pioneer in the class, granisetron faces competition from newer agents with improved profiles but maintains cost competitiveness.
- Regulatory Trends: Successful navigation of clinical trials and approvals in new indications will be pivotal for future market expansion.
- Investment Outlook: Opportunities exist in formulation innovation and emerging markets; however, price competition from generics remains a significant factor.
References
[1] ClinicalTrials.gov, NCT04876429, Efficacy of Granisetron in Chemotherapy-Induced Nausea, Phase III, Status: Ongoing.
[2] ClinicalTrials.gov, NCT04582588, Granisetron vs. Palonosetron in CINV, Phase II, Status: Completed.
[3] ClinicalTrials.gov, NCT03344777, Pediatric Use of Granisetron in PONV, Phases I/II, Status: Recruiting.
